Patient of the Month for November: Americo Blancato
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Americo Blancato shares his story.
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Americo Blancato shares his story.
In this issue of LRG Science, we present additional commentary on our Sept. issue: "It's Time to Rethink Placebos in Advanced GIST".
Caring for the Caregiver focused on common challenges caregivers experience and how these challenges can often lead to burnout, while also highlighting the impact of COVID-19.
This video is about understanding the role of mutations and biomarker testing in GIST. Knowing the driving force behind each individual’s tumors is not just important, it is critical in determining the most effective treatment for your mutation.
The Life Raft Group (LRG) is providing you with this information to let you know that comprehensive genomic profiling, also known as biomarker testing or molecular testing, is a crucial step in understanding the genomic factors that play a role in a GIST diagnosis. Bayer Pharmaceuticals, in partnership with The Life Raft Group (LRG), has extended a research collaboration to broaden access to comprehensive genomic testing (CGT) for Gastrointestinal Stromal Tumor (GIST) patients.
On Thursday, October 7th at 2pm ET the LRG held “Conversations with the LRG". In this presentation, our Global GIST Mentors discussed the role of the GIST Mentor and how one can assist you on your GIST journey.
In this issue of LRG Science: based on current studies, this article asserts the belief that placebos do not benefit patients with advanced disease.
Dr. Jason Sicklick of Moores Cancer Center at UC San Diego dedicated his new research lab to the memory of GISTer Merak Melikian Hatounian.
The welfare of our members and staff is of utmost importance to us and due to ongoing pandemic, we have decided to take the precaution of postponing our GIST DO IT Walk which was scheduled for October 2nd.
A recent study in Cancer Genetics, International initiative for a curated SDHB variant database improving the diagnosis of hereditary paraganglioma and pheochromocytoma, is important for GIST patients who carry a germline SDHB mutation